Could an HIV drug tame brain inflammation in Alzheimer's?
NCT ID NCT07553338
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a drug called leronlimab is safe for people with mild Alzheimer's or mild cognitive impairment. Twenty volunteers over age 50 will receive weekly injections for 12 weeks. Researchers will use brain scans and blood tests to see if the drug lowers brain inflammation, which is thought to play a role in Alzheimer's. This is the first time leronlimab is being tested in Alzheimer's patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
leronlimab (a lab-made antibody)
What this could lead to
If it works, this could point toward a treatment that slows Alzheimer's by reducing brain inflammation.
What could go wrong
This is a very small, early-phase trial focused on safety, not effectiveness. The drug may not reduce inflammation or help thinking skills, and side effects are unknown in this group.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Weill Cornell Medicine Brain Health Imaging Institute
RECRUITINGNew York, New York, 10065, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••